
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV has demonstrated a commitment to advancing its pipeline of gene therapies, particularly through positive data and supportive feedback regarding its lead product, AMT-130, which management asserts holds a compelling efficacy profile for Huntington's disease. The company's strategic collaboration with Bristol Myers Squibb in developing treatments for cardiovascular diseases further solidifies its growth potential in significant markets. Additionally, encouraging developments in other trials, such as the Phase 1/2a GenTLE trial for AMT-260 in mesial temporal lobe epilepsy, coupled with a favorable regulatory environment, underscore a robust outlook for the company's future financial performance.
Bears say
The analysis indicates a negative outlook for uniQure NV due to significant regulatory and developmental delays concerning its gene therapy, AMT-130, which could hinder future revenue generation as management has withdrawn prior guidance for a pivotal submission timeline. The company continues to face financial risks as it remains in the clinical stage without any market-ready products, resulting in cumulative losses since its inception. Additionally, increased competition from both existing and emerging therapies targeting similar indications poses a risk to its potential market penetration and pricing strategy.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares